Insights into Heterocyclic Compounds for Cancer and COVID-19 Treatment: Design, Synthesis and Molecular Targets
A special issue of Molecules (ISSN 1420-3049). This special issue belongs to the section "Organic Chemistry".
Deadline for manuscript submissions: closed (30 April 2024) | Viewed by 618
Special Issue Editor
Interests: molecular wires; electronic properties; optical properties; cation radical; near-ir region; cyclic voltammetry; ultraviolet-visible–near-infrared spectroscopy; parp-1 inhibitor; antiproliferative; apoptosis; autophagy; molecular docking; cancer; drug design
Special Issues, Collections and Topics in MDPI journals
Special Issue Information
Dear Colleagues,
Pyrimidines have been extensively studied and used as scaffolds for the design and synthesis of various drugs. For example, the antiviral drug acyclovir and the anticancer drug 5-fluorouracil both contain a pyrimidine ring in their structure. Other pyrimidine-containing drugs include dihydropyrimidine calcium channel blockers, which are used to treat hypertension, and antihistamines, which are used to treat allergies. Moreover, several pyrimidine-based compounds have been identified as potential anticancer agents via targeting different cellular pathways involved in cancer development and progression. For instance, some pyrimidine derivatives have been designed as inhibitors of the epidermal growth factor receptor (EGFR) and other tyrosine kinases, which are overexpressed in certain types of cancer, including lung, breast, and colorectal cancer. These inhibitors include Erlotinib, Gefitinib, and Lapatinib, which have been approved for clinical use in the treatment of lung and breast cancer. Recently, studies have shown that pyrimidines have an important role in the development of treatments and vaccines against COVID-19.
Dr. Sameh Abdelwahed
Guest Editor
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Molecules is an international peer-reviewed open access semimonthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2700 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
Keywords
- pyrimidine
- enzyme inhibitor
- antiproliferative
- apoptosis
- autophagy
- molecular docking
- computational chemistry
- drug development COVID-19
- coronavirus
- pandemic
